AYTU BIOPHARMA, INC Amortization of Deferred Charges
AYTU BIOPHARMA, INC (AYTU) reported Amortization of Deferred Charges of $1.60 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfDeferredCharges · last filed 2023-11-14
- AYTU BIOPHARMA, INC amortization of deferred charges for the quarter ending 2023-09-30 was $1.60M, a 6.67% increase year-over-year.
- AYTU BIOPHARMA, INC amortization of deferred charges for the quarter ending 2023-06-30 was $1.50M, a 11.76% decline year-over-year.
- AYTU BIOPHARMA, INC amortization of deferred charges for the quarter ending 2023-03-31 was $1.50M, a 25.00% decline year-over-year.
- AYTU BIOPHARMA, INC amortization of deferred charges for the quarter ending 2022-12-31 was $1.50M, a 25.00% decline year-over-year.
- AYTU BIOPHARMA, INC amortization of deferred charges for fiscal 2023 was $6.10M, a 21.79% decline from fiscal 2022.
- AYTU BIOPHARMA, INC amortization of deferred charges for fiscal 2022 was $7.80M, a 9.86% increase from fiscal 2021.
- AYTU BIOPHARMA, INC amortization of deferred charges for fiscal 2021 was $7.10M.
| Period end | Amortization of Deferred Charges 3 month | Amortization of Deferred Charges 6 month | Amortization of Deferred Charges 9 month | Amortization of Deferred Charges 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.60M 10-Q · filed 2023-11-14 | $3.10M derived: sum of 2 quarters · filed 2023-11-14 | $4.60M derived: sum of 3 quarters · filed 2023-11-14 | $6.10M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $3.00M derived: sum of 2 quarters · filed 2023-10-12 | $4.50M derived: sum of 3 quarters · filed 2023-10-12 | $6.10M 10-K · filed 2023-10-12 |
| 2023-03-31 | $1.50M 10-Q · filed 2023-05-11 | $3.00M derived: sum of 2 quarters · filed 2023-05-11 | $4.60M 10-Q · filed 2023-05-11 | $6.20M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $1.50M 10-Q · filed 2023-02-21 | $3.00M 10-Q · filed 2023-02-21 | $4.70M derived: sum of 3 quarters · filed 2023-11-14 | $6.70M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-09-30 | $1.50M 10-Q · filed 2023-11-14 | $3.20M derived: sum of 2 quarters · filed 2023-11-14 | $5.20M derived: sum of 3 quarters · filed 2023-11-14 | $7.20M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $3.70M derived: sum of 2 quarters · filed 2023-10-12 | $5.70M derived: sum of 3 quarters · filed 2023-10-12 | $7.80M 10-K · filed 2023-10-12 |
| 2022-03-31 | $2.00M 10-Q · filed 2023-05-11 | $4.00M derived: sum of 2 quarters · filed 2023-05-11 | $6.10M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $2.00M 10-Q · filed 2023-02-21 | $4.10M 10-Q · filed 2023-02-21 | ||
| 2021-09-30 | $2.10M 10-Q/A · filed 2023-02-21 | |||
| 2021-06-30 | $7.10M 10-K · filed 2022-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |